Search

Biomedical discovery is fraught with challenges stemming from diverse data types and siloed analysis. In this study, we explored common biomedical data tasks and pain points that could be addressed to elevate data quality, enhance sharing, streamline analysis, and foster collaboration across stakeholders. We recruited fifteen professionals from various biomedical roles and industries to participate in sixty-minute semi-structured interviews, which involved an assessment of their challenges, needs, and tasks as well as a brainstorm exercise to validate each professional's research process. We applied a qualitative analysis of individual interviews using an inductive-deductive thematic coding approach for emerging themes. We identified a common set of challenges related to procuring and validating data, applying new analysis techniques and navigating varied computational environments, distributing results effectively and reproducibly, and managing the flow of data across phases of the data lifecycle. Our findings emphasize the importance of secure data sharing and facilities for collaboration throughout the discovery process. Our identified pain points provide researchers with an opportunity to align workstreams and enhance research data lifecycles to conduct biomedical discovery. We conclude our study with a summary of key actionable recommendations to tackle multiomic data challenges across the stages and phases of biomedical discovery., Competing Interests: Declarations. Competing interests: The authors declare no competing interests., (© 2025. The Author(s).)

Purpose: Inflammatory bowel disease (IBD) has been considered a relative contraindication to radiation therapy (RT) because of the potential greater risk of RT-induced toxicities. This study aimed to assess acute toxicity outcomes in patients with IBD treated with abdominal/pelvic RT., Methods and Materials: After institutional review board approval, patients with IBD who received RT to the abdomen/pelvis were identified from an institutional research repository, and their electronic medical records were reviewed. The IBD cohort was matched 1:1 with controls according to all of the following: RT, gender, disease site, age, and year of RT. Acute toxicity was defined as toxicity occurring within 3 months of RT. Primary outcomes were assessed via univariable logistic regression models and the predicted probability of acute toxicity and acute gastrointestinal (GI) toxicity were plotted for the most significant covariates. IBD and control cohorts were compared on demographic and toxicity variables using χ 2 /Fisher exact tests and Kruskal-Wallis tests where appropriate., Results: We identified 62 patients with a median age of 64 years (IQR, 54-70 years) who received RT from 2006 to 2022. Patients were treated with intensity modulated RT (38; 61.3%), 3-dimensional conformal RT (12; 19.4%), and stereotactic body RT/brachytherapy (12; 19.4%). After RT, 28 (45.2%) and 23 (37.1%) patients experienced grade ≥2 acute (any) and acute GI toxicity, respectively. Higher overall RT dose and RT dose to small bowel were found to be significantly associated with increased risk of grade ≥2 acute toxicities (OR, 1.041 per unit Gy; 95% CI, 1.005-1.084; P = .034 and OR, 1.046; 95% CI, 1.018-1.082; P = .003, respectively). Between IBD and control cohorts, there were no significant differences in grade ≥2 acute (any) and acute GI toxicities (P = .710 and P = .704, respectively)., Conclusions: In patients with IBD treated with abdominal/pelvic RT for malignancy, RT was effective and well-tolerated. RT treatment planning should carefully consider the location(s) of IBD inflammation and dose to bowel structures, in particular, dose to the small bowel., (Copyright © 2024 Elsevier Inc. All rights reserved.)